Search Results
EndoERN, APHP Consortium Pitie Salpetriere Hospital, Necker Hospital, Paris, France
Search for other papers by Nathalie Ly in
Google Scholar
PubMed
EndoERN, APHP Consortium Pitie Salpetriere Hospital, Necker Hospital, Paris, France
Search for other papers by Sophie Dubreuil in
Google Scholar
PubMed
EndoERN, APHP Consortium Pitie Salpetriere Hospital, Necker Hospital, Paris, France
Sorbonne University, Paris, France
Search for other papers by Philippe Touraine in
Google Scholar
PubMed
://doi.org/10.1016/j.fertnstert.2004.03.026 ) 16 Wirén L Boguszewski CL Johannsson G . Growth hormone (GH) replacement therapy in GH-deficient women during pregnancy . Clinical Endocrinology 2002 57 235 – 239 . ( https://doi.org/10.1046/j.1365
Search for other papers by Charlotte Höybye in
Google Scholar
PubMed
Search for other papers by Andreas F H Pfeiffer in
Google Scholar
PubMed
Search for other papers by Diego Ferone in
Google Scholar
PubMed
Search for other papers by Jens Sandahl Christiansen in
Google Scholar
PubMed
Search for other papers by David Gilfoyle in
Google Scholar
PubMed
Search for other papers by Eva Dam Christoffersen in
Google Scholar
PubMed
Search for other papers by Eva Mortensen in
Google Scholar
PubMed
Search for other papers by Jonathan A Leff in
Google Scholar
PubMed
Search for other papers by Michael Beckert in
Google Scholar
PubMed
and 70 years with a body mass index (BMI) of 19.0–36.0 kg/m 2 ) diagnosed with AGHD (defined according to the Growth Hormone Research Society Consensus Guidelines of 1998 and 2007) ( 1 , 12 ) who were stable on GH replacement therapy for at least 3
Search for other papers by M Ahmid in
Google Scholar
PubMed
Search for other papers by C G Perry in
Google Scholar
PubMed
Search for other papers by S F Ahmed in
Google Scholar
PubMed
Search for other papers by M G Shaikh in
Google Scholar
PubMed
Wilton P Kims Study Group & KIMS International Board The infuence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density . Journal of Bone and Mineral
Search for other papers by Kennett Sprogøe in
Google Scholar
PubMed
Search for other papers by Eva Mortensen in
Google Scholar
PubMed
Search for other papers by David B Karpf in
Google Scholar
PubMed
Search for other papers by Jonathan A Leff in
Google Scholar
PubMed
.1517/14712598.2013.795941 23662811 7 Reed ML Merriam GR Kargi AY . Adult growth hormone deficiency – benefits, side effects, and risks of growth hormone replacement . Frontiers in Endocrinology 2013 4 64 . 23761782 8 Guyda HJ . Four decades of growth hormone therapy
Search for other papers by Charlotte Höybye in
Google Scholar
PubMed
Search for other papers by Beverly M K Biller in
Google Scholar
PubMed
Search for other papers by Jean-Marc Ferran in
Google Scholar
PubMed
Search for other papers by Murray B Gordon in
Google Scholar
PubMed
Search for other papers by Nicky Kelepouris in
Google Scholar
PubMed
Search for other papers by Navid Nedjatian in
Google Scholar
PubMed
Search for other papers by Anne H Olsen in
Google Scholar
PubMed
Search for other papers by Matthias M Weber in
Google Scholar
PubMed
quality of life, an adverse lipid profile and an increased risk for cardiovascular (CV)-associated disease, diabetes and metabolic syndrome vs healthy adults ( 4 , 5 , 6 , 7 ). The use of growth hormone (GH) replacement therapy in AGHD has been shown
Search for other papers by Kevin C J Yuen in
Google Scholar
PubMed
Search for other papers by Gudmundur Johannsson in
Google Scholar
PubMed
Search for other papers by Ken K Y Ho in
Google Scholar
PubMed
Search for other papers by Bradley S Miller in
Google Scholar
PubMed
Search for other papers by Ignacio Bergada in
Google Scholar
PubMed
Search for other papers by Alan D Rogol in
Google Scholar
PubMed
S . Effects of adult growth hormone deficiency and replacement therapy on the cardiometabolic risk profile . Pituitary 2022 25 211 – 228 . ( https://doi.org/10.1007/s11102-022-01207-1 ) 7 Ho KK & 2007 GH Deficiency Consensus Workshop
Search for other papers by Izabelle Lövgren in
Google Scholar
PubMed
Radiotherapy Related Research, The Christie NHS Foundation Trust, Manchester, UK
Search for other papers by Azadeh Abravan in
Google Scholar
PubMed
Search for other papers by Abigail Bryce-Atkinson in
Google Scholar
PubMed
Radiotherapy Related Research, The Christie NHS Foundation Trust, Manchester, UK
Search for other papers by Marcel van Herk in
Google Scholar
PubMed
-term quality of life for the patients but also benefit the healthcare system financially by reducing the overall treatment costs, as life-long hormone replacement therapy may be avoided. This review aims to address the late effects of cranial RT on the
Search for other papers by Mark R Postma in
Google Scholar
PubMed
Search for other papers by Pia Burman in
Google Scholar
PubMed
Search for other papers by André P van Beek in
Google Scholar
PubMed
2010 95 3664 – 3674 . ( https://doi.org/10.1210/jc.2009-2506 ) 14 Burman P Johansson AG Siegbahn A Vessby B Karlsson FA . Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women . Journal of Clinical
Search for other papers by Sarmistha Banerjee in
Google Scholar
PubMed
Search for other papers by Allison M Hayes in
Google Scholar
PubMed
Search for other papers by Bernard H Shapiro in
Google Scholar
PubMed
of CYP3A4 and CYP3A5 ( 3 , 4 ) while in the case of mice, males express greater levels of CYP2D9 ( 2 ). (ii) The sexual dimorphisms in CYP expression are determined by sex differences in the circulating growth hormone (GH) profiles in adulthood. More
Search for other papers by Anastasia P Athanasoulia-Kaspar in
Google Scholar
PubMed
Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Ludwig-Maximilians-Universität München, Munich, Germany
Search for other papers by Matthias K Auer in
Google Scholar
PubMed
Search for other papers by Günter K Stalla in
Google Scholar
PubMed
Search for other papers by Mira Jakovcevski in
Google Scholar
PubMed
(unsubstituted gonadotropic deficiency + menopausal status not receiving replacement therapy) (yes/no), hypothyroidism, overt GHD (substituted GHD and unsubstituted GHD) (yes/no), growth hormone dose, IGF-1-SDS, adrenal insufficiency (yes/no), daily total